Eloxx reports $56.3m cash as exaluren advances in two rare kidney diseases
The company says its balance sheet should last into 2028, covering a mid-2027 Alport readout and a planned Q3 2027 start in polycystic kidney disease.
Eloxx Pharmaceuticals ended the third quarter of 2026 with $56.3 million in cash, which it expects to fund operations into 2028. The figure came with the company's results on 16 November, and it matters because exaluren, its lead asset, is now moving in two separate kidney indications.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Eloxx Pharmaceuticals, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.